Risk of dopamine dysregulation syndrome (DDS) associated with the use of dopaminergic medicines used for the treatment of Parkinson’s disease (PD).

Risk of dopamine dysregulation syndrome (DDS) associated with the use of dopaminergic medicines used for the treatment of Parkinson’s disease (PD).

2021 Nov

Download latest version
Document Number: DHCPL
Version: 1
Date Updated: 25/11/2021
File Type: pdf
Category: Communication To Health Care Professionals
Unit: Pharmacovigilance